drugset / Trial / NCT02437227
Dose Escalation Study With Expansion to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of CCT3833
Phase 1
Completed
31 enrolled
Royal Marsden NHS Foundation Trust
Biomedical Research Centre for Cancer · collabInstitute of Cancer Research, United Kingdom · collabWellcome Trust · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
The study is a first in man, dose escalation study to evaluate the safety, tolerability and how the drug works in the body in patients with all solid tumours. The aim of this study is to determine the most effective dose of the study drug that can then be further investigated in patients with advanced melanoma.
Timeline
- Start
- 2015-04-15
- Primary completion
- 2017-12
- Completion
- 2018-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CCT3833 | Small molecule | 20 mg | Oral |
| Subject | CCT3833 | Small molecule | 40 mg | Oral |
| Subject | CCT3833 | Small molecule | 75 mg | Oral |
| Subject | CCT3833 | Small molecule | 150 mg | Oral |
| Subject | CCT3833 | Small molecule | 300 mg | Oral |
| Subject | CCT3833 | Small molecule | 600 mg | Oral |
| Subject | CCT3833 | Small molecule | 900 mg | Oral |
| Subject | CCT3833 | Small molecule | 1350 mg | Oral |